ZFYVE16

ZFYVE16 (endofin) is a FYVE-domain endosomal protein that governs endosomal membrane trafficking and intersects with TGF-β/Smad signaling (PMID:11546807, PMID:29247407). It is recruited to early endosomes through direct, PI3P-specific binding by its FYVE domain: a single C753S substitution abolishes both PI3P binding and endosomal association, and PI3-kinase inhibition by wortmannin displaces the protein (PMID:11546807). Functionally, its overexpression drives endosome aggregation/fusion and accumulation of endocytosed EGF in enlarged vesicles, marking it as a regulator of endosomal membrane traffic (PMID:11546807). Although it co-localizes with SARA on early endosomes, it neither co-immunoprecipitates with SARA nor associates with Smad2 or behaves like SARA in TGF-β signaling (PMID:11546807); instead it binds Smad4 and modulates Smad2/3–Smad4 complex formation (PMID:29247407). At the organismal level, Zfyve16 knockout mice show impaired B-lymphoid cell proliferation and an increased peripheral T cell proportion, linking the protein to hematopoietic regulation consistent with its TGF-β role (PMID:29247407). ZFYVE16 also associates with LAMP1- and LAMP2A-positive late endosomal/lysosomal compartments in human neuronal axons (PMID:41537223). Beyond these findings, the structural basis and detailed mechanism of its Smad4 interaction have not been characterized in the available corpus.

1. 2001 High

   Established how ZFYVE16 is targeted to membranes, defining it as a PI3P-dependent early endosomal protein and identifying the FYVE domain residue required for lipid binding.

   Evidence In vitro liposome binding, point mutagenesis (C753S), wortmannin treatment and immunofluorescence in cultured cells

   PMID:11546807

   Open questions at the time

   • Does not define the dynamics or regulation of endosomal recruitment in vivo
   • No structural model of the FYVE–PI3P interaction provided
2. 2001 Medium

   Distinguished ZFYVE16 from the related FYVE protein SARA, showing it does not share SARA's Smad2/TGF-β adaptor role despite co-localizing on endosomes.

   Evidence Reciprocal co-immunoprecipitation (negative), co-localization imaging, and TGF-β signaling assays in co-expressing cells

   PMID:11546807

   Open questions at the time

   • Negative results from a single study
   • Did not exclude weaker or transient SARA interactions
3. 2001 Medium

   Provided functional evidence that ZFYVE16 regulates endosomal membrane traffic by showing overexpression remodels endosome morphology and endocytic cargo flux.

   Evidence Overexpression in COS7 cells with fluorescent EGF endocytosis assay and immunofluorescence

   PMID:11546807

   Open questions at the time

   • Overexpression phenotype may not reflect endogenous function
   • Mechanism driving endosome aggregation/fusion not resolved
4. 2017 Medium

   Connected ZFYVE16 to TGF-β signaling through Smad4 binding and demonstrated a physiological role in hematopoiesis using a knockout mouse.

   Evidence Zfyve16 knockout mice with flow cytometry and B cell proliferation assays; Smad4 interaction cited as prior finding

   PMID:29247407

   Open questions at the time

   • Smad4-binding claim lacks primary data reproduced in this study
   • Causal link between Smad4 interaction and the B/T cell phenotype not directly established
5. 2026 Medium

   Extended ZFYVE16's compartmental association to late endosomal/lysosomal membranes in neurons, identifying it as a LAMP1/LAMP2A-proximal protein in axons.

   Evidence LOV-Turbo proximity labelling with LAMP1 and LAMP2A baits, mass spectrometry, validated in hiPSC-derived cortical neurons

   PMID:41537223

   Open questions at the time

   • Proximity does not establish direct binding to LAMP1/LAMP2A
   • Functional role of ZFYVE16 at late endosomes/lysosomes in neurons unresolved

• How ZFYVE16's endosomal trafficking activity mechanistically couples to its Smad4 binding and its physiological roles in immune cells and neurons remains unknown.
• No structural or biochemical characterization of the Smad4 interaction
• No reconciliation of early-endosomal versus late-endosomal/lysosomal roles
• Direct binding partners at the lysosome not defined